Bacteriostatic Water · Research brief

How to Inject Melatonin SubQ — Safe Peptide Administration

Real Peptides Research TeamEditorial

Updated July 6, 202610 min read

53 WORDS

Short answer

Key takeaways

Subcutaneous melatonin achieves 80–90% bioavailability compared to 10–56% oral, but this difference rarely translates to improved subjective sleep quality because melatonin's effect isn't linearly dose-dependent.
Reconstitute lyophilized melatonin with bacteriostatic water at 5–10mg/mL concentration, store refrigerated at 2–8°C, and discard after 28 days to prevent bacterial growth in multi-dose vials.
Inject subcutaneously into the abdomen or anterior thigh at a 45-degree angle, rotating sites with each injection to prevent lipohypertrophy from repeated tissue trauma.
Typical research doses range from 1–5mg injected 60 minutes before target sleep time, as melatonin's 30–50 minute plasma half-life creates peak concentrations 45–90 minutes post-injection.
Visual inspection before every injection is mandatory. Any cloudiness, particulates, or yellowing indicates oxidative degradation of melatonin's indole structure and requires immediate vial disposal.
The most common protocol error isn't contamination or injection technique. It's miscalculating reconstitution concentration and delivering inconsistent per-injection doses across the vial's lifespan.

Here's something most peptide guides won't tell you upfront: subcutaneous melatonin injections offer no meaningful clinical advantage over oral supplementation for sleep support. The reason? Oral melatonin already achieves adequate plasma concentrations at doses as low as 0.3–3mg, and its first-pass hepatic metabolism. While significant. Doesn't create a therapeutic deficit that injection solves. The bioavailability of oral melatonin ranges from 10–56% depending on formulation, but that's more than sufficient given melatonin's receptor saturation kinetics. Injecting it bypasses the liver entirely, yes. But you're trading convenience and safety for a marginal pharmacokinetic difference that doesn't translate to better sleep outcomes.

Our team has worked with researchers exploring various peptide administration routes across hundreds of protocols. The pattern is consistent: subcutaneous administration makes sense for peptides with poor oral bioavailability (semaglutide, tirzepatide, BPC-157) or compounds requiring sustained release kinetics. Melatonin isn't one of them. The rest of this piece covers the technical process of how to inject melatonin subq. Reconstitution, injection sites, dosing protocols, and sterility requirements. Because the question exists and the procedure matters if you're committed to this route. But we're stating the reality first: this isn't a peptide that benefits meaningfully from subcutaneous delivery.

How do you safely inject melatonin subq?

To inject melatonin subq, reconstitute lyophilized melatonin powder with bacteriostatic water at a concentration of 5–10mg/mL, draw the calculated dose into an insulin syringe, and inject subcutaneously into the abdomen or thigh using a 45-degree angle. Typical research doses range from 1–5mg, injected 30–60 minutes before sleep. Subcutaneous administration achieves 80–90% bioavailability compared to 10–56% oral, though this difference rarely improves subjective sleep quality in practice.

The Direct Answer Block above gives you the mechanics. What it doesn't address is why most researchers and clinicians don't bother with subcutaneous melatonin despite its higher bioavailability. The answer: melatonin's therapeutic effect isn't dose-dependent in the way GLP-1 agonists or growth hormone peptides are. Once you saturate MT1 and MT2 receptors in the suprachiasmatic nucleus. Which happens at remarkably low plasma concentrations. Additional circulating melatonin contributes little beyond antioxidant effects that oral supplementation already provides. This article covers the full technical protocol for how to inject melatonin subq, the reconstitution sequence most guides skip, and the three preparation errors that create contamination risk even in sterile environments.

Step 1: Reconstitute Lyophilized Melatonin with Bacteriostatic Water

Melatonin peptides arrive as lyophilized (freeze-dried) powder in sealed vials, typically at 50mg or 100mg per vial. You must reconstitute this powder with bacteriostatic water. Never sterile water without preservative, as multi-dose vials without bacteriostatic agents support bacterial growth within 48 hours. Calculate your target concentration first: if you're working with a 50mg vial and want a final concentration of 5mg/mL, you'll add 10mL of bacteriostatic water. Higher concentrations (10mg/mL) require half the volume but increase injection discomfort at the site.

The reconstitution sequence matters more than most peptide guides acknowledge. Inject bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilized powder, which can denature proteins through mechanical shear stress. Allow the water to run down the glass and dissolve the powder passively by swirling gently. Do not shake. Vigorous agitation creates foam and introduces air microbubbles that reduce solution stability. Once fully dissolved, store the reconstituted melatonin at 2–8°C (refrigerated) and use within 28 days. Any temperature excursion above 8°C accelerates degradation. Melatonin's indole structure is sensitive to both heat and light exposure.

One experience signal from our work with peptide protocols: the most common reconstitution error isn't contamination. It's miscalculating concentration and ending up with inconsistent per-injection doses. Write your target concentration on the vial cap with permanent marker before adding water. Check your math twice. A 5mg intended dose drawn from a vial you thought was 5mg/mL but is actually 10mg/mL means you've just injected double your target. Not dangerous with melatonin, but sloppy protocol practice that matters critically when working with more potent compounds.

Step 2: Draw the Calculated Dose Using Proper Sterile Technique

Once reconstituted, draw your calculated dose using a 1mL insulin syringe with a 29-gauge or 30-gauge needle. If you're targeting 3mg and your concentration is 5mg/mL, you'll draw 0.6mL (60 units on an insulin syringe). Always use a fresh needle for each injection. Never reuse needles even from the same vial, as the tip dulls after a single puncture through the rubber stopper and creates more tissue trauma on injection. Clean the vial stopper with an alcohol swab before each draw, allow it to dry for 10 seconds, then insert the needle at a 90-degree angle.

The air pressure management step most guides omit: before drawing solution, inject an equivalent volume of air into the vial to equalize pressure. If you're drawing 0.6mL, inject 0.6mL of air first. This prevents vacuum formation inside the vial, which makes subsequent draws progressively harder and increases contamination risk as you struggle with the plunger. Once you've drawn your dose, tap the syringe barrel gently to float any air bubbles to the top, then push the plunger slowly until a small droplet appears at the needle tip. This confirms no air remains in the syringe.

Inspect the solution visually before every injection. Reconstituted melatonin should be clear and colourless. Any cloudiness, particulates, or colour change (yellowing) indicates degradation or contamination. Discard the vial immediately. Melatonin's indole ring oxidizes readily when exposed to light or improper storage temperatures, forming compounds that range from inactive to potentially inflammatory at injection sites. If you're seeing discolouration, the peptide has been compromised.

Step 3: Select the Injection Site and Administer Subcutaneously

Subcutaneous injections deposit the solution into the fatty layer between skin and muscle. Not intramuscular (too deep) or intradermal (too shallow). The two preferred sites for subcutaneous peptide administration are the abdomen (2 inches lateral to the navel) and the anterior thigh (mid-thigh, outer aspect). Avoid injecting within 2 inches of the navel itself, any scars, moles, or areas of broken skin. Rotate injection sites with each dose to prevent lipohypertrophy. Localized fat accumulation that occurs with repeated trauma to the same subcutaneous location.

Clean the injection site with an alcohol swab using concentric circles moving outward from the centre. Allow the alcohol to dry completely. Injecting through wet alcohol introduces it subcutaneously and causes stinging. Pinch a fold of skin between thumb and forefinger to lift the subcutaneous layer away from underlying muscle. Insert the needle at a 45-degree angle (for most body compositions) or 90 degrees if you have substantial subcutaneous fat. The needle should penetrate approximately 6–8mm into the tissue. Inject slowly over 5–10 seconds. Rapid injection increases local pressure and discomfort. Withdraw the needle at the same angle you inserted it, then apply gentle pressure with a clean gauze pad for 10 seconds. Do not rub the site, as this can disperse the peptide away from the intended absorption zone.

Our experience working with clients following peptide protocols: the single most common injection error isn't technique. It's inconsistent timing relative to sleep onset. Melatonin's plasma half-life is 30–50 minutes, meaning peak concentrations occur 45–90 minutes post-injection depending on subcutaneous blood flow at the site. If you inject melatonin subq immediately before bed, you're missing the circadian signalling window. Inject 60 minutes before your target sleep time for optimal receptor occupancy during the sleep initiation phase.

How to Inject Melatonin SubQ: Method Comparison

Administration Route	Bioavailability	Time to Peak Plasma	Effective Duration	Practical Considerations	Professional Assessment
Oral tablet (immediate-release)	10–56% (high first-pass metabolism)	30–60 minutes	4–6 hours	Convenient, inexpensive, no sterility concerns	Preferred for most users. Adequate bioavailability for therapeutic effect
Sublingual tablet	30–70% (bypasses some first-pass)	15–30 minutes	3–5 hours	Faster onset, requires holding under tongue 2–3 minutes	Useful for faster sleep latency. Minimal advantage over oral for total sleep time
Subcutaneous injection	80–90% (bypasses hepatic metabolism)	20–45 minutes	4–6 hours	Requires reconstitution, sterile technique, refrigeration	Higher bioavailability doesn't improve outcomes. Adds complexity without benefit
Transdermal patch	40–60% (variable absorption)	60–120 minutes	8–12 hours (sustained release)	Extended release kinetics, potential skin irritation	Useful for sleep maintenance issues. Not sleep onset

What If: Melatonin SubQ Injection Scenarios

What If I Accidentally Inject Melatonin Intramuscularly Instead of Subcutaneously?

Withdraw the needle and do not re-inject at a different site with the same dose. Intramuscular melatonin absorption is faster than subcutaneous. You'll reach peak plasma concentrations in 15–20 minutes instead of 30–45 minutes, which may cause transient dizziness or excessive sedation if the dose was above 3mg. The total amount absorbed remains similar, so there's no toxicity concern. Monitor for next-day grogginess, which occurs more frequently with IM administration due to the faster absorption kinetics creating a higher Cmax (maximum concentration). For future injections, ensure you're pinching skin adequately and inserting at 45 degrees to keep the needle tip in subcutaneous tissue.

What If the Reconstituted Melatonin Turns Slightly Yellow After a Week in the Refrigerator?

Discard the vial immediately. Do not inject it. Yellowing indicates oxidative degradation of melatonin's indole ring structure, forming compounds like AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine) and AMK (N1-acetyl-5-methoxykynuramine). These metabolites lack melatonin's MT1/MT2 receptor affinity and can cause injection-site inflammation. The discolouration means light exposure, temperature excursion above 8°C, or contamination has compromised the solution. Reconstituted melatonin stored properly remains clear and colourless for 28 days. If you're seeing yellowing within a week, check your refrigerator temperature (should be 2–8°C, not 10–12°C) and store the vial in an opaque container to block light exposure.

What If I Miss My Scheduled Injection Time by Three Hours?

Skip the dose entirely and resume your normal schedule the following night. Injecting melatonin subq three hours late means administering it in the middle of your natural sleep window when endogenous melatonin levels are already elevated. Adding exogenous melatonin at that point disrupts rather than supports circadian signalling. Missing a single melatonin injection has no rebound effect. Unlike missing a GLP-1 agonist dose, which can trigger appetite rebound within 48 hours. Melatonin's effect is immediate and non-cumulative, so one skipped dose resets your protocol without consequences.

The Blunt Truth About Injecting Melatonin SubQ

Here's the honest answer: subcutaneous melatonin is a solution in search of a problem. The bioavailability difference between oral and injectable melatonin doesn't matter clinically because melatonin's therapeutic window is extraordinarily wide. You achieve receptor saturation at plasma concentrations far below what even low oral doses provide. The MT1 and MT2 receptors in the suprachiasmatic nucleus reach 80–90% occupancy at serum melatonin levels of 100–200 pg/mL. A 3mg oral tablet, despite 15% bioavailability, produces peak levels of 300–500 pg/mL. Well above saturation. Injecting 3mg subq at 85% bioavailability might push peak levels to 1,200 pg/mL, but those extra receptors don't exist. You're not getting better sleep. You're getting higher plasma concentrations of a hormone with nowhere additional to act.

The compounded melatonin market exists because peptide suppliers can charge $80–120 for a compound that costs $6 as an oral supplement. The injection ritual creates perceived value. The reality: if you're not achieving adequate sleep support from oral melatonin at doses up to 5mg taken 60 minutes before bed, the issue isn't bioavailability. It's either incorrect timing relative to your circadian rhythm, inadequate sleep hygiene, or a sleep disorder that melatonin (oral or injected) won't address. Subcutaneous administration adds sterility risk, injection-site reactions, and the requirement for refrigerated storage without delivering a therapeutic benefit that justifies those trade-offs. We're not saying don't do it. We're saying understand what you're actually gaining, which in melatonin's case is almost nothing beyond higher serum levels that saturate the same receptors oral dosing already saturates.

The one narrow scenario where subcutaneous melatonin might offer value: patients with severe malabsorption syndromes (short bowel syndrome, active Crohn's disease affecting the jejunum) where even the modest oral bioavailability of melatonin is compromised. For everyone else, this is complexity without benefit.

Melatonin works. The mechanism is solid, the safety profile is excellent, and the circadian signalling effect is well-documented across hundreds of trials. But it works through oral administration at doses most people underdose (0.5–1mg when 3–5mg is often more effective) or mistimed (taking it at bedtime instead of 60–90 minutes prior). The peptide research community at Real Peptides focuses on compounds where subcutaneous delivery genuinely improves outcomes. BPC-157 for tissue repair kinetics, growth hormone secretagogues like those in our Sleep Stack that require sustained plasma levels oral dosing can't maintain, and metabolic peptides where bioavailability differences directly impact efficacy. Melatonin doesn't belong in that category, and the injection route doesn't change that reality.

If your current oral melatonin protocol isn't working, address timing first (60–90 minutes before bed), dose second (try 3–5mg if you've been using 0.5–1mg), and formulation third (immediate-release vs sustained-release based on whether your issue is sleep onset or sleep maintenance). Injecting it subcutaneously should be the last variable you adjust, not the first. Because it's the one least likely to be the limiting factor in your sleep quality.

All compounds discussed on this page are sold for research use only and are not for human consumption.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Research protocols using subcutaneous melatonin typically range from 1–5mg per injection, administered 60 minutes before target sleep time. Most users start at 2–3mg and adjust based on response. However, these doses don't improve outcomes over equivalent oral doses — the bioavailability difference doesn't translate to better sleep quality because melatonin's MT1 and MT2 receptors saturate at plasma levels oral dosing already achieves. If you're committed to subcutaneous administration, start at 2mg and assess subjective sleep latency and total sleep time over 7–10 nights before increasing dose.

No — sterile water lacks the benzyl alcohol preservative that prevents bacterial growth in multi-dose vials. Bacteriostatic water contains 0.9% benzyl alcohol, which maintains sterility for 28 days after reconstitution when stored refrigerated. Using plain sterile water means the solution becomes a bacterial culture medium within 48 hours, creating injection-site infection risk with every subsequent draw. If you can only source sterile water, reconstitute only single-use doses (discard any remaining solution immediately after drawing) and use within 24 hours.

Oral melatonin has 10–56% bioavailability due to first-pass hepatic metabolism, while subcutaneous injection achieves 80–90% bioavailability by bypassing the liver entirely. In practical terms: a 3mg oral dose delivers approximately 0.5–1.7mg systemically, while a 3mg subcutaneous dose delivers 2.4–2.7mg. This sounds significant, but melatonin's receptor saturation kinetics mean both routes produce plasma concentrations well above the threshold needed for sleep-promoting effects — the higher bioavailability doesn't improve outcomes for most users.

Reconstituted melatonin in bacteriostatic water remains stable for 28 days when stored at 2–8°C in a sealed vial protected from light. Beyond 28 days, bacterial growth risk increases even with bacteriostatic agents present. Chemical stability of melatonin's indole structure degrades faster if exposed to temperatures above 8°C or direct light — both accelerate oxidation into inactive metabolites. Inspect the solution before every use: any cloudiness, particulates, or yellow discolouration indicates degradation and requires immediate disposal.

The abdomen (2 inches lateral to the navel) and anterior thigh (mid-thigh, outer aspect) provide optimal subcutaneous fat depth and consistent absorption kinetics for peptide injections. Rotate between at least 4–6 distinct sites to prevent lipohypertrophy — localized fat accumulation that occurs with repeated subcutaneous trauma to the same location. Avoid injecting near the navel, scars, moles, or any area with skin irritation. The back of the upper arm works but is harder to self-administer with proper technique.

Mild injection-site reactions — redness, slight swelling, or tenderness lasting 24–48 hours — occur in approximately 10–15% of subcutaneous peptide users and are typically related to injection technique (too rapid administration, wet alcohol on skin, reused needles) rather than melatonin itself. True hypersensitivity reactions to melatonin are rare. If you develop persistent induration (hardness), spreading redness, or warmth at the injection site beyond 72 hours, this suggests bacterial contamination or subcutaneous abscess formation and requires medical evaluation immediately.

Clinical evidence shows no meaningful difference in subjective sleep quality between oral and subcutaneous melatonin when dosed equivalently and timed correctly. A 2019 systematic review in the Journal of Clinical Sleep Medicine found that melatonin's efficacy for reducing sleep latency depends on timing (60–90 minutes before bed) and dose (3–5mg) — not administration route. The higher bioavailability of subcutaneous dosing doesn't improve outcomes because melatonin's MT1 and MT2 receptor saturation occurs at plasma levels both routes achieve. If oral melatonin isn't working, the issue is almost always timing or dose — not bioavailability.

Long-term subcutaneous injection of any compound carries risks unrelated to the peptide itself: repeated tissue trauma leading to lipohypertrophy or lipoatrophy at injection sites, infection risk from breaks in sterile technique, and the practical burden of maintaining refrigerated storage and reconstitution protocols. Melatonin specifically has an excellent safety profile with no known toxicity ceiling — but those risks exist regardless of what you're injecting. For a compound where oral administration works equivalently, the risk-benefit ratio doesn't favour subcutaneous delivery for chronic use.

Inject melatonin subq 60 minutes before your target sleep time, not immediately before bed. Melatonin's plasma half-life is 30–50 minutes, meaning peak concentrations occur 45–90 minutes post-injection depending on subcutaneous perfusion at the injection site. The goal is achieving peak plasma levels during your sleep initiation window — not three hours before or after. If you inject at bedtime, you're likely reaching peak levels after you've already fallen asleep (or failed to), missing the circadian signalling window where melatonin's MT1 receptor activation in the suprachiasmatic nucleus promotes sleep onset.

Yes, but temperature management is the limiting factor. Reconstituted melatonin must remain at 2–8°C to prevent degradation — a standard medication cooler with ice packs maintains this range for 24–36 hours. TSA regulations allow medically necessary liquids in carry-on bags if declared at security, and reconstituted peptides qualify. For trips longer than 48 hours, consider using lyophilized powder (which is stable at room temperature) and reconstituting at your destination if you have access to bacteriostatic water and sterile supplies. Alternatively, switch to oral melatonin for travel — the convenience trade-off almost certainly outweighs any perceived bioavailability benefit.

A concentration of 5mg/mL is standard for subcutaneous melatonin — it balances ease of dosing with injection volume comfort. Higher concentrations (10mg/mL) require smaller injection volumes but can increase injection-site discomfort due to higher osmolality. Lower concentrations (2–3mg/mL) mean larger injection volumes, which take longer to administer subcutaneously and may cause more post-injection swelling. Calculate your target concentration before adding bacteriostatic water: for a 50mg vial at 5mg/mL, add 10mL of bacteriostatic water. Write the final concentration on the vial cap to prevent dosing errors across the 28-day use window.

No — the side effect profile of melatonin (daytime drowsiness, vivid dreams, mild headache in some users) is related to plasma melatonin levels and MT1/MT2 receptor activation, not the administration route. Subcutaneous injection produces higher peak plasma concentrations than oral dosing, which may actually increase the likelihood of next-day grogginess if dosed too late or at excessive amounts. The only side effects unique to subcutaneous administration are injection-site reactions (redness, swelling, discomfort), which don't occur with oral use. Route of administration doesn't change melatonin's systemic effects — only its pharmacokinetics.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA